相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung-Jue Bang et al.
INVESTIGATIONAL NEW DRUGS (2011)
Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study
S. Rao et al.
ANNALS OF ONCOLOGY (2010)
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo
Zev A. Wainberg et al.
CLINICAL CANCER RESEARCH (2010)
Epirubicin, Oxaliplatin, and Capecitabine With or Without Panitumumab for Advanced Esophagogastric Cancer: Dose-Finding Study for the Prospective Multicenter, Randomized, Phase II/III REAL-3 Trial
Alicia F. C. Okines et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I Pharmacologic and Biologic Study of Ramucirumab (IMC-1121B), a Fully Human Immunoglobulin G1 Monoclonal Antibody Targeting the Vascular Endothelial Growth Factor Receptor-2
Jennifer L. Spratlin et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Multicenter Phase II Study of Everolimus in Patients With Previously Treated Metastatic Gastric Cancer
Toshihiko Doi et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cancer research in the global village
Alastair J. Munro et al.
LANCET (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
S-W Han et al.
BRITISH JOURNAL OF CANCER (2009)
The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38
Melissa J. LaBonte et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
Jin Won Kim et al.
CANCER LETTERS (2008)
Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells
Isaya Hashimoto et al.
EUROPEAN JOURNAL OF CANCER (2008)
HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells
Thomas Bachleitner-Hofmann et al.
MOLECULAR CANCER THERAPEUTICS (2008)
A phase II study of gefitinib monotherapy in advanced Esophageal adenocarcinoma: Evidence of gene expression, cellular, and clinical response
David R. Ferry et al.
CLINICAL CANCER RESEARCH (2007)
Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model
Sven A. Lang et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C. Pinto et al.
ANNALS OF ONCOLOGY (2007)
EGFR targeting therapies: Monoclonal antibodies versus tyrosine kinase inhibitors similarities and differences
Olivier Dassonville et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Evaluation of HER-2 gene status in gastric carcinoma using immunohistochemistry, fluorescence in situ hybridization, and real-time quantitative polymerase chain reaction
Min A. Kim et al.
HUMAN PATHOLOGY (2007)
Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinorna
Manish A. Shah et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 study group
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Phase II trial of erlotinib in gastroesophageal junction and gastric adenocarcinomas: SWOG 0127
Tomislav Dragovich et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Pharmacodynamic studies of gefitinib in tumor biopsy specimens from patients with advanced gastric carcinoma
Federico Rojo et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Effect of target dynamics on pharmacokinetics of a novel therapeutic antibody against the epidermal growth factor receptor: Implications for the mechanisms of action
Jeroen J. Lannnerts van Bueren et al.
CANCER RESEARCH (2006)
Chemotherapy in advanced gastric cancer: A systematic review and meta-analysis based on aggregate data
Anna D. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Amplification of HER-2 in gastric carcinoma:: association with Topoisomerase IIα gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
M Tanner et al.
ANNALS OF ONCOLOGY (2005)
Epidermal growth factor receptor expression correlates with poor survival in gastric adenocarcinoma from Mexican patients:: a multivariate analysis using a standardized immunlohistochemical detection system
A Gamboa-Dominguez et al.
MODERN PATHOLOGY (2004)
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor
LB Saltz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma:: results of a randomized phase II study
C Pozzo et al.
ANNALS OF ONCOLOGY (2004)
Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic,gastric cancer:: A Federation Francophone de Cancerologie Digestive Group Study -: FFCD 9803
O Bouche et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Angiogenesis in health and disease
P Carmeliet
NATURE MEDICINE (2003)
Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells
M Akagi et al.
BRITISH JOURNAL OF CANCER (2003)
VEGF-Trap: A VEGF blocker with potent antitumor effects
J Holash et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial
SR Bramhall et al.
BRITISH JOURNAL OF CANCER (2002)
Expression of MMP-2 is associated with progression and lymph node metastasis of gastric carcinoma
SP Mönig et al.
HISTOPATHOLOGY (2001)
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
S Zucker et al.
ONCOGENE (2000)
Transcription factor NF-kappa B is constitutively activated in acute lymphoblastic leukemia cells
U Kordes et al.
LEUKEMIA (2000)
分享论文
